{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:45:36Z","timestamp":1794271536432,"version":"4.9.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bjid.2023.102774","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T17:39:13Z","timestamp":1683308353000},"page":"102774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-6430","authenticated-orcid":false,"given":"Elahe","family":"Akbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Seyedinkhorasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-7406","authenticated-orcid":false,"given":"Azam","family":"Bolhassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2023.102774_bib0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/14760584.2020.1712199","article-title":"HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy","volume":"19","author":"Moretti","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bjid.2023.102774_bib0002","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2020.1015","article-title":"Unified model of short-and long-term HIV viral rebound for clinical trial planning","volume":"18","author":"Conway","year":"2021","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.bjid.2023.102774_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000917","article-title":"Perforin expression directly ex vivo by HIV-specific CD8+ T-cells is a correlate of HIV elite control","volume":"6","author":"Hersperger","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bjid.2023.102774_bib0004","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14712598.2016.1193594","article-title":"HIV-1 immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine","volume":"16","author":"Graziani","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bjid.2023.102774_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/vaccines9020134","article-title":"HIV mRNA vaccines-progress and future paths","volume":"9","author":"Mu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bjid.2023.102774_bib0006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/psb.1919","article-title":"Forty years on: how close is an HIV vaccine?","volume":"32","author":"Greener","year":"2021","journal-title":"Prescriber"},{"key":"10.1016\/j.bjid.2023.102774_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14760584.2020.1718497","article-title":"Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges","volume":"19","author":"Pitisuttithum","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bjid.2023.102774_bib0008","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2023.102774_bib0009","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","article-title":"CD8+ T cells in HIV control, cure and prevention","volume":"20","author":"Collins","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bjid.2023.102774_bib0010","doi-asserted-by":"crossref","first-page":"eaaf1483","DOI":"10.1126\/scitranslmed.aaf1483","article-title":"Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection","volume":"9","author":"Parsons","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bjid.2023.102774_bib0011","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/COH.0000000000000696","article-title":"Considerations for successful therapeutic immunization in HIV cure","volume":"16","author":"Mothe","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.bjid.2023.102774_bib0012","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/vaccines9091026","article-title":"Current status of HIV-1 vaccines","volume":"9","author":"Hargrave","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bjid.2023.102774_bib0013","first-page":"1","article-title":"HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine","author":"Cafaro","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bjid.2023.102774_bib0014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/14760584.2015.962520","article-title":"Peptide\u2013MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development","volume":"14","author":"Reguzova","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bjid.2023.102774_bib0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10529-021-03143-9","article-title":"In silico design and in vitro expression of novel multiepitope DNA constructs based on HIV-1 proteins and Hsp70 T-cell epitopes","volume":"43","author":"Akbari","year":"2021","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.bjid.2023.102774_bib0016","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1255512","article-title":"Immunologic strategies for HIV-1 remission and eradication","volume":"345","author":"Barouch","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bjid.2023.102774_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00375-19","article-title":"Advances toward curing HIV-1 infection in tissue reservoirs","volume":"94","author":"Henderson","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.bjid.2023.102774_bib0018","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.3389\/fmicb.2019.03060","article-title":"Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs","volume":"10","author":"Ait-Ammar","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bjid.2023.102774_bib0019","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14760584.2017.1322513","article-title":"New challenges in therapeutic vaccines against HIV infection","volume":"16","author":"Leal","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bjid.2023.102774_bib0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/COH.0000000000000748","article-title":"CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies","volume":"17","author":"Rutishauser","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.bjid.2023.102774_bib0021","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature01441","article-title":"CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bjid.2023.102774_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2022.933418","article-title":"How to break free: HIV-1 escapes from innovative therapeutic approaches","author":"Magro","year":"2022","journal-title":"Front Virol."},{"key":"10.1016\/j.bjid.2023.102774_bib0023","doi-asserted-by":"crossref","first-page":"e25797","DOI":"10.1002\/jia2.25797","article-title":"Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review","volume":"24","author":"Derking","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.bjid.2023.102774_bib0024","doi-asserted-by":"crossref","first-page":"38946","DOI":"10.18632\/oncotarget.7793","article-title":"Perspectives for immunotherapy: which applications might achieve an HIV functional cure?","volume":"7","author":"Vieillard","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bjid.2023.102774_bib0025","first-page":"1","article-title":"Progress towards a therapeutic HIV DNA vaccine","author":"Munson","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bjid.2023.102774_bib0026","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11904-021-00545-2","article-title":"Immunologic control of HIV-1: what have we learned and can we induce it?","volume":"18","author":"Rogan","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"10.1016\/j.bjid.2023.102774_bib0027","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/21645515.2019.1666957","article-title":"T cell-based strategies for HIV-1 vaccines","volume":"16","author":"Korber","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.bjid.2023.102774_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101412","article-title":"Immunological approaches to HIV cure","volume":"51","author":"Ward","year":"2021","journal-title":"Semin Immunol"},{"key":"10.1016\/j.bjid.2023.102774_bib0029","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","article-title":"Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection","volume":"32","author":"Leal","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2023.102774_bib0030","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/infdis\/jiaa333","article-title":"The emerging role for CTL epitope specificity in HIV cure efforts","volume":"223","author":"Kaseke","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bjid.2023.102774_bib0031","series-title":"Advances in HIV and AIDS Control","article-title":"Artificial epitope-based immunogens in HIV-vaccine design","author":"Karpenko","year":"2018"},{"key":"10.1016\/j.bjid.2023.102774_bib0032","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.omtm.2021.04.018","article-title":"Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines","volume":"21","author":"Wee","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.bjid.2023.102774_bib0033","first-page":"38","article-title":"B109 Vacc-4x and Vacc-C5: two peptide-based therapeutic HIV vaccine candidates","volume":"62","author":"Sommerfelt","year":"2013","journal-title":"JAIDS"},{"key":"10.1016\/j.bjid.2023.102774_bib0034","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.molimm.2020.01.013","article-title":"Comparative analysis of two HIV-1 multiepitope polypeptides for stimulation of immune responses in BALB\/c mice","volume":"119","author":"Kardani","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.bjid.2023.102774_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/COH.0000000000000444","article-title":"Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies","volume":"13","author":"Seddiki","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.bjid.2023.102774_bib0036","doi-asserted-by":"crossref","first-page":"ftac021","DOI":"10.1093\/femspd\/ftac021","article-title":"Immunopotentiation by linking Hsp70 T-cell epitopes to Gag-Pol-Env-Nef-Rev multiepitope construct and increased IFN-gamma secretion in infected lymphocytes","volume":"80","author":"Akbari","year":"2022","journal-title":"Pathog Dis"},{"key":"10.1016\/j.bjid.2023.102774_bib0037","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"Letourneau","year":"2007","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.bjid.2023.102774_bib0038","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/eji.201040344","article-title":"Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques","volume":"40","author":"Rosario","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bjid.2023.102774_bib0039","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14760584.2019.1675518","article-title":"Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials","volume":"18","author":"Hanke","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bjid.2023.102774_bib0040","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/mtm.2016.61","article-title":"Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T-cells in African adults","volume":"3","author":"Mutua","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.bjid.2023.102774_bib0041","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T-cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"Borthwick","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.bjid.2023.102774_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bjid.2023.102774_bib0043","doi-asserted-by":"crossref","first-page":"21171","DOI":"10.7448\/IAS.20.1.21171","article-title":"Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA. HIVconsv, in antiretroviral therapy-treated subjects","volume":"20","author":"Hancock","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.bjid.2023.102774_bib0044","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bjid.2023.102774_bib0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fimmu.2020.00418","article-title":"In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 Kick&Kill clinical trial","volume":"11","author":"Ros\u00e1s-Umbert","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.bjid.2023.102774_bib0046","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3389\/fimmu.2020.00823","article-title":"HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02)","volume":"11","author":"Mothe","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.bjid.2023.102774_bib0047","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40265-020-01322-y","article-title":"Novel approaches towards a functional cure of HIV\/AIDS","volume":"80","author":"Bailon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bjid.2023.102774_bib0048","doi-asserted-by":"crossref","unstructured":"Fidler S., St\u00f6hr W., Pace M., et al. A randomized comparison of antiretroviral therapy alone versus antiretroviral therapy with a'Kick-and-Kill'Approach, on measures of the HIV reservoir amongst participants with recent HIV infection: the RIVER Trial. 2019.","DOI":"10.2139\/ssrn.3439560"},{"key":"10.1016\/j.bjid.2023.102774_bib0049","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","article-title":"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial","volume":"395","author":"Fidler","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2023.102774_bib0050","unstructured":"Fidler S., Stohr W., Pace M., et al. A randomised controlled trial comparing the impact of antiretroviral therapy (ART) with a \u2018kick-and-kill'approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial. 2018."},{"key":"10.1016\/j.bjid.2023.102774_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-018-0429-y","article-title":"CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication","volume":"15","author":"Murakoshi","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.bjid.2023.102774_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-9-208","article-title":"Definition of the viral targets of protective HIV-1-specific T cell responses","volume":"9","author":"Mothe","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.bjid.2023.102774_bib0053","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1128\/JVI.00020-15","article-title":"Clinical control of HIV-1 by cytotoxic T cells specific for multiple conserved epitopes","volume":"89","author":"Murakoshi","year":"2015","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.bjid.2023.102774_bib0054","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/14712598.2014.885946","article-title":"Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines","volume":"14","author":"Hanke","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bjid.2023.102774_bib0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.bjid.2023.102774_bib0056","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/mt.2016.3","article-title":"Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection","volume":"24","author":"Ondondo","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.bjid.2023.102774_bib0057","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/aid.2006.0075","article-title":"HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2\/IFN-\u03b3-secreting CD4+ and CD4+\/CD8+ T cells in humans after lipopeptide vaccination","volume":"23","author":"Gahery","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.bjid.2023.102774_bib0058","doi-asserted-by":"crossref","first-page":"11220","DOI":"10.1128\/JVI.77.20.11220-11231.2003","article-title":"Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized","volume":"77","author":"Gah\u00e9ry-S\u00e9gard","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.bjid.2023.102774_bib0059","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1097\/QAD.0b013e32833ce566","article-title":"Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial","volume":"24","author":"Salmon-C\u00e9ron","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2023.102774_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jim.2010.11.002","article-title":"Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine","volume":"365","author":"Cobb","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bjid.2023.102774_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008011","article-title":"Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination","volume":"15","author":"Surenaud","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bjid.2023.102774_bib0062","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.3389\/fimmu.2019.02911","article-title":"The safety and immunogenicity of GTU\u00ae MultiHIV DNA vaccine delivered by transcutaneous and intramuscular injection with or without electroporation in HIV-1 positive subjects on suppressive ART","volume":"10","author":"Haidari","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bjid.2023.102774_bib0063","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1016\/j.vaccine.2011.07.025","article-title":"Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01","volume":"29","author":"Fomsgaard","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.bjid.2023.102774_bib0064","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.clim.2012.12.005","article-title":"Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection","volume":"146","author":"Karlsson","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bjid.2023.102774_bib0065","doi-asserted-by":"crossref","first-page":"e6950","DOI":"10.1371\/journal.pone.0006950","article-title":"A novel liposome-based adjuvant CAF01 for induction of CD8+ cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A* 0201 transgenic mice","volume":"4","author":"Gram","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bjid.2023.102774_bib0066","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1089\/aid.2013.0076","article-title":"Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau","volume":"29","author":"Rom\u00e1n","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.bjid.2023.102774_bib0067","series-title":"Peptide Antibodies","first-page":"351","article-title":"Therapeutic HIV peptide vaccine","author":"Fomsgaard","year":"2015"},{"key":"10.1016\/j.bjid.2023.102774_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-10-107","article-title":"Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation","volume":"10","author":"Pleguezuelos","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.bjid.2023.102774_bib0069","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1016\/j.vaccine.2013.09.057","article-title":"Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial","volume":"31","author":"Boffito","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.bjid.2023.102774_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-015-0392-5","article-title":"A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques","volume":"13","author":"Mothe","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.bjid.2023.102774_bib0071","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAD.0000000000001276","article-title":"Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)","volume":"31","author":"Guardo","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2023.102774_bib0072","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/vaccines7040209","article-title":"Therapeutic vaccine in chronically HIV-1-infected patients: a randomized, double-blind, placebo-controlled phase IIa trial with HTI-TriMix","volume":"7","author":"de Jong","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bjid.2023.102774_bib0073","first-page":"48","article-title":"A placebo-controlled ATI trial of HTI vaccines in early treated HIV infection","author":"Bailon","year":"2021","journal-title":"Topics Antiviral Medicine"},{"key":"10.1016\/j.bjid.2023.102774_bib0074","first-page":"1","article-title":"iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy","volume":"20","author":"De Jong","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.bjid.2023.102774_bib0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.bjid.2023.102774_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-018-0455-9","article-title":"Antibody-mediated prevention and treatment of HIV-1 infection","volume":"15","author":"Gruell","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.bjid.2023.102774_bib0077","doi-asserted-by":"crossref","first-page":"e25797","DOI":"10.1002\/jia2.25797","article-title":"Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review","volume":"24","author":"Derking","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.bjid.2023.102774_bib0078","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.vaccine.2014.12.045","article-title":"Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides","volume":"33","author":"Hanson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.bjid.2023.102774_bib0079","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1473-3099(13)70343-8","article-title":"Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4\u00d7: a phase 2 randomised, double-blind, placebo-controlled trial","volume":"14","author":"Pollard","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2023.102774_bib0080","first-page":"964","article-title":"Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection","volume":"11","author":"Jones","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bjid.2023.102774_bib0081","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112556","article-title":"Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial","volume":"9","author":"Brekke","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bjid.2023.102774_bib0082","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210965","article-title":"Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption","volume":"14","author":"Rockstroh","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bjid.2023.102774_bib0083","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bjid.2023.102774_bib0084","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jinf.2017.09.004","article-title":"Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs","volume":"75","author":"Tapia","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.bjid.2023.102774_bib0085","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.vaccine.2009.10.129","article-title":"A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting","volume":"28","author":"Goldstein","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.bjid.2023.102774_bib0086","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.4161\/hv.21616","article-title":"HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia","volume":"8","author":"Goldstein","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.bjid.2023.102774_bib0087","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4161\/hv.19184","article-title":"Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naive and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects","volume":"8","author":"Goldstein","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.bjid.2023.102774_bib0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2316-x","article-title":"The therapeutic HIV Env C5\/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I\/II clinical study","volume":"17","author":"Brekke","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2023.102774_bib0089","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/14760584.2021.1945448","article-title":"The current and future role of nanovaccines in HIV-1 vaccine development","volume":"20","author":"Karch","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bjid.2023.102774_bib0090","first-page":"1","article-title":"Nanoparticle vaccines for inducing HIV-1 neutralizing antibodies","volume":"7","author":"Brinkkemper","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bjid.2023.102774_bib0091","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm-2016-0381","article-title":"Vaccine nanoparticles for protection against HIV infection","volume":"12","author":"Aikins","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bjid.2023.102774_bib0092","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trsl.2020.04.008","article-title":"Therapeutic Vaccines for the Treatment of HIV","volume":"223","author":"Chen","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.bjid.2023.102774_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101211","article-title":"Broadly neutralizing antibodies against HIV-1 and concepts for application","volume":"54","author":"Gruell","year":"2022","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bjid.2023.102774_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104012","article-title":"HIV cure trial mergers: spotlighting the epigenetics of latency reversal","volume":"79","author":"Denton","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bjid.2023.102774_bib0095","doi-asserted-by":"crossref","DOI":"10.1111\/jmp.12613","article-title":"The role of latency reversal in HIV cure strategies","author":"Tanaka","year":"2022","journal-title":"J Med Primatology"},{"key":"10.1016\/j.bjid.2023.102774_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.bjid.2023.102774_bib0097","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bjid.2023.102774_bib0098","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/COH.0000000000000641","article-title":"Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission","volume":"15","author":"Gunst","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.bjid.2023.102774_bib0099","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11904-021-00569-8","article-title":"Analytical treatment interruption in HIV trials: statistical and study design considerations","volume":"18","author":"Zheng","year":"2021","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S141386702300034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S141386702300034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:00:41Z","timestamp":1761408041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S141386702300034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S141386702300034X"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2023.102774","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2023.102774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102774"}}